注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Virios Therapeutics Inc(原名:Virios Therapeutics LLC)是一家处于开发阶段的生物技术公司,专注于推进抗病毒疗法,以治疗与病毒引发的异常免疫反应相关的疾病,例如纤维肌痛(FM)。该公司的主要开发候选药物是泛昔洛韦和塞来昔布的固定剂量组合IMC-1。IMC-1是一种联合抗病毒疗法,旨在协同抑制单纯疱疹病毒1(HSV-1)的激活和复制。HSV-1是慢性疾病的根本原因,如FM、肠易激疾病(IBS)、慢性疲劳综合征和功能性躯体综合征。该公司正在为患有纤维肌痛的人开发其候选药物IMC-1。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Joel D. Baines | - | - | Member of Scientific Advisory Board |
Dedra Stefanie Buchwald | - | - | Member of Scientific Advisory Board |
Greg Duncan | 56 | 2018 | Chairman & CEO |
Lesley Mussio Arnold | - | - | Member of Scientific Advisory Board |
Michael C. Camilleri | - | - | Member of Scientific Advisory Board |
David R. Keefer | 70 | 2018 | Independent Director |
Richard James Whitley | 77 | 2020 | Member of Scientific Advisory Board & Independent Director |
Daniel J. Clauw | - | - | Chair of Scientific Advisory Board |
William L. Pridgen | 62 | 2012 | Founder & Director |
Abel De La Rosa | 60 | 2020 | Independent Director |
John C. Thomas | 69 | 2020 | Independent Director |
Richard Alan Burch | 67 | 2014 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核